Institutional investors purchased a net $1.3 million shares of RGEN during the quarter ended March 2015 and now own 94.84% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FIDELITY MANAGEMENT & RESEARCH C... Bought 964.8 Thousand shares of Repligen Corp
STATE STREET GLOBAL ADVISORS LTD... Bought 212.00 shares of Repligen Corp
COMPASS EFFICIENT MODEL PORTFOLI... Bought 82.00 shares of Repligen Corp